124 results
8-K
EX-99.1
7raqdu231di
2 Nov 23
Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
7:37am
8-K
EX-10.3
se5r psgblhe6s0l
3 May 21
Departure of Directors or Certain Officers
7:18am
8-K
EX-10.2
g81end zu2agcq3sb
3 May 21
Departure of Directors or Certain Officers
7:18am
8-K
EX-99.1
45x3a
11 Feb 21
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
g9y0en79ugzpito1o2l
11 Jan 21
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
8:06am
8-K
EX-99.1
oobhfee
18 Dec 20
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
11:58am
8-K
EX-99.1
6omufuho6aqncr18 5x
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm